Interaction analysis of high-risk pathological features on adjuvant chemotherapy survival benefit in stage II colon cancer patients: a multi-center, retrospective study

被引:0
|
作者
Li, Kexuan [1 ]
Zhao, Fuqiang [2 ]
Guo, Yuchen [3 ]
Wu, Qingbin [4 ]
Luo, Shuangling [5 ,6 ,7 ]
Zhang, Junling [8 ]
Li, Heli [9 ]
Hu, Shidong [10 ]
Wu, Bin [1 ]
Lin, Guole [1 ]
Qiu, Huizhong [1 ]
Niu, Beizhan [1 ]
Sun, Xiyu [1 ]
Xu, Lai [1 ]
Lu, Junyang [1 ]
Du, Xiaohui [10 ]
Wang, Zheng [9 ]
Wang, Xin [8 ]
Kang, Liang [5 ,6 ,7 ]
Wang, Ziqiang [4 ]
Wang, Quan [3 ]
Liu, Qian [2 ]
Xiao, Yi [1 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Gen Surg, Div Colorectal Surg, 1 Shuai Fu Yuan Rd, Beijing 100730, Peoples R China
[2] Chinese Acad Med Sci & Peking Union Med Coll, Natl Canc Ctr, Natl Clin Res Ctr Canc, Canc Hosp,Dept Diagnost Radiol, 17 Panjiayuan Nanli, Beijing 100021, Peoples R China
[3] First Hosp Jilin Univ, Gen Surg Ctr, Dept Gastrointestinal Surg, 1 Xin Min Ave, Changchun 130021, Peoples R China
[4] Sichuan Univ, West China Hosp, Colorectal Canc Ctr, Dept Gen Surg, 37 Guo Xue Xiang, Chengdu 610041, Peoples R China
[5] Sun Yat sen Univ, Affiliated Hosp 6, Dept Gen Surg Colorectal Surg, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[6] Sun Yat sen Univ, Affiliated Hosp 6, Guangdong Prov Key Lab Colorectal & Pelv Floor Dis, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[7] Sun Yat sen Univ, Affiliated Hosp 6, Biomed Innovat Ctr, 26 Yuan Cun Er Heng Rd, Guangzhou 510655, Peoples R China
[8] Peking Univ First Hosp, Dept Gastrointestinal Surg, 8 Xi Shi Ku St, Beijing 100034, Peoples R China
[9] Huazhong Univ Sci & Technol, Union Hosp, Tongji Med Coll, Dept Gastrointestinal Surg, 1277 Jiefang Ave, Wuhan 430022, Peoples R China
[10] Chinese Peoples Liberat Army PLA Gen Hosp, Med Ctr 1, Dept Gen Surg, 28 Fu Xing Rd, Beijing 100853, Peoples R China
基金
中国国家自然科学基金;
关键词
Colon cancer; High-risk pathological features; Adjuvant chemotherapy; PERINEURAL INVASION; PREDICTIVE FACTOR; PROGNOSTIC-FACTOR; OXALIPLATIN; FLUOROURACIL; LEUCOVORIN; OUTCOMES; THERAPY; TRIAL;
D O I
10.1186/s12885-023-11196-4
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background We aimed to analyze the benefit of adjuvant chemotherapy in high-risk stage II colon cancer patients and the impact of high-risk factors on the prognostic effect of adjuvant chemotherapy. Methods This study is a multi-center, retrospective study, A total of 931 patients with stage II colon cancer who underwent curative surgery in 8 tertiary hospitals in China between 2016 and 2017 were enrolled in the study. Cox proportional hazard model was used to assess the risk factors of disease-free survival (DFS) and overall survival (OS) and to test the multiplicative interaction of pathological factors and adjuvant chemotherapy (ACT). The additive interaction was presented using the relative excess risk due to interaction (RERI). The Subpopulation Treatment Effect Pattern Plot (STEPP) was utilized to assess the interaction of continuous variables on the ACT effect. Results A total of 931 stage II colon cancer patients were enrolled in this study, the median age was 63 years old (interquartile range: 54-72 years) and 565 (60.7%) patients were male. Younger patients (median age, 58 years vs 65 years; P < 0.001) and patients with the following high-risk features, such as T4 tumors (30.8% vs 7.8%; P < 0.001), grade 3 lesions (36.0% vs 22.7%; P < 0.001), lymphovascular invasion (22.1% vs 6.8%; P < 0.001) and perineural invasion (19.4% vs 13.6%; P = 0.031) were more likely to receive ACT. Patients with perineural invasion showed a worse OS and marginally worse DFS (hazardous ratio [HR] 2.166, 95% confidence interval [CI] 1.282-3.660, P = 0.004; HR 1.583, 95% CI 0.985-2.545, P = 0.058, respectively). Computing the interaction on a multiplicative and additive scale revealed that there was a significant interaction between PNI and ACT in terms of DFS (HR for multiplicative interaction 0.196, p = 0.038; RERI, -1.996; 95%CI, -3.600 to -0.392) and OS (HR for multiplicative interaction 0.112, p = 0.042; RERI, -2.842; 95%CI, -4.959 to -0.725). Conclusions Perineural invasion had prognostic value, and it could also influence the effect of ACT after curative surgery. However, other high-risk features showed no implication of efficacy for ACT in our study.
引用
收藏
页数:12
相关论文
共 50 条
  • [31] Duration of oxaliplatin-based adjuvant chemotherapy in patients with Stage III or high-risk Stage II resected colon cancer
    Moretto, Roberto
    Falcone, Alfredo
    Cremolini, Chiara
    INTERNATIONAL JOURNAL OF CANCER, 2020, 146 (09) : 2652 - 2654
  • [32] Survival benefit of adjuvant chemotherapy for patients with poorly differentiated stage IIA colon cancer
    Liu, Qi
    Luo, Dakui
    An, Hongyin
    Zhang, Sheng
    Cai, Sanjun
    Li, Qingguo
    Li, Xinxiang
    JOURNAL OF CANCER, 2019, 10 (05): : 1209 - 1215
  • [33] Adjuvant chemotherapy for high-risk stage II and stage III colon cancer: timing of initiation and optimal duration
    Cruz, Jan Paolo M.
    Pales, Chris George C.
    Kim, Kwang Min
    Kim, Young Wan
    JOURNAL OF BUON, 2018, 23 (03): : 568 - 573
  • [34] Significance of high-risk factors other than lymph node metastasis on impact of prognosis in stage II-II colon cancer: Multi-center retrospective cohort study
    Kim, I.
    Bae, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S98 - S99
  • [35] A national evaluation of the predictors of compliance and survival from adjuvant chemotherapy in high-risk stage II colon cancer: A National Cancer Database (NCDB) analysis
    de Paula, Thais Reif
    Gorroochurn, Prakash
    Haas, Eric M.
    Keller, Deborah S.
    SURGERY, 2022, 172 (03) : 859 - 868
  • [36] National Evaluation of the Predictors of Compliance and Survival from Adjuvant Chemotherapy in High-Risk Stage II Colon Cancer: A National Cancer Database (NCDB) Analysis
    de Paula, Thais Reif
    Simon, Hillary
    da Luz, Magda Maria Profeta
    Keller, Deborah S.
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2020, 231 (04) : E103 - E104
  • [37] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Liao, Leen
    Tang, Jinghua
    Hong, Zhigang
    Jiang, Wu
    Li, Yuan
    Kong, Lingheng
    Han, Kai
    Hou, Zhenlin
    Zhang, Chenzhi
    Zhou, Chi
    Zhang, Linjie
    Sui, Qiaoqi
    Xiao, Binyi
    Mei, Weijian
    Yu, Jiehai
    Yang, Wanjun
    Pan, Zhizhong
    Ding, Pei-Rong
    BMC CANCER, 2024, 24 (01)
  • [38] The effects of oxaliplatin-based adjuvant chemotherapy in high-risk stage II colon cancer with mismatch repair-deficient: a retrospective study
    Leen Liao
    Jinghua Tang
    Zhigang Hong
    Wu Jiang
    Yuan Li
    Lingheng Kong
    Kai Han
    Zhenlin Hou
    Chenzhi Zhang
    Chi Zhou
    Linjie Zhang
    Qiaoqi Sui
    Binyi Xiao
    Weijian Mei
    Jiehai Yu
    Wanjun Yang
    Zhizhong Pan
    Pei-Rong Ding
    BMC Cancer, 24
  • [39] Adjuvant Chemotherapy Is Associated With Improved Survival in Patients With Stage II Colon Cancer
    Casadaban, Leigh
    Rauscher, Garth
    Aklilu, Mebea
    Villenes, Dana
    Freels, Sally
    Maker, Ajay V.
    CANCER, 2016, 122 (21) : 3277 - 3287
  • [40] ADJUVANT CHEMOTHERAPY IMPROVES SURVIVAL IN PATIENTS WITH STAGE II COLON CANCER.
    Mckenzie, S.
    Mailey, B.
    Artinyan, A.
    Pigazzi, A.
    Garcia-Aguilar, J.
    Kim, J.
    DISEASES OF THE COLON & RECTUM, 2010, 53 (04) : 615 - 615